0001104659-22-063871.txt : 20220523 0001104659-22-063871.hdr.sgml : 20220523 20220523163021 ACCESSION NUMBER: 0001104659-22-063871 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220520 ITEM INFORMATION: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220523 DATE AS OF CHANGE: 20220523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001372514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36672 FILM NUMBER: 22952107 BUSINESS ADDRESS: STREET 1: 1371 EAST 2100 SOUTH STREET 2: SUITE 200 CITY: SALT LAKE CITY STATE: UT ZIP: 84105 BUSINESS PHONE: (781) 788-8869 MAIL ADDRESS: STREET 1: 1371 EAST 2100 SOUTH STREET 2: SUITE 200 CITY: SALT LAKE CITY STATE: UT ZIP: 84105 FORMER COMPANY: FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060811 8-K 1 tm2216631d1_8k.htm FORM 8-K
0001372514 false 0001372514 2022-05-20 2022-05-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): May 20, 2022

 

KIORA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction of incorporation)

 

001-36672   98-0443284
(Commission File Number)   (IRS Employer Identification No.)

 

1371 East 2100 South

Suite 200

Salt Lake City, Utah 84105 

 

84105

(Address of principal executive offices)   (Zip Code)

 

(781) 788-9043

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:
Common Stock, $0.01 par value   KPRX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

  

Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

 

On May 20, 2022, the Audit Committee of the Board of Directors (the “Audit Committee”) of Kiora Pharmaceuticals, Inc. (the “Company”), after discussion with management of the Company and the Company’s independent registered public accounting firm, EisnerAmper LLP (“EisnerAmper”), concluded that the Company’s previously issued audited consolidated financial statements as of and for the fiscal years ended December 31, 2021 and December 31, 2020 included in the Company’s Annual Reports on Form 10-K for such periods and unaudited condensed consolidated interim financial statements as of and for the fiscal periods ended March 31, 2021, June 30, 2021 and September 30, 2021 included in the Company’s Quarterly Reports on Form 10-Q for such periods should no longer be relied upon. Similarly, earnings releases, and investor communications describing the financial statements for the periods described above should no longer be relied upon.

 

As part of preparing its condensed consolidated financial statements as of and for the quarter ended March 31, 2022, the Company identified inadvertent errors in the accounting for certain contingent consideration.

 

In connection with the Company’s acquisition of Panoptes Pharma Ges.m.b.H in December 2020, shares of the Company’s common stock that were held back at closing and that will be issued on the 18-month anniversary of the acquisition, subject to deduction for any indemnification claims, post-closing adjustments and other specified matters (the “Holdback Shares”), were recorded as a liability of $1.353 million. Upon further evaluation, the Company determined that the Holdback Shares should have been accounted for as equity.

 

Additionally, in connection with the Company’s acquisition of Jade Therapeutics, Inc. (“Jade”) in March 2016, the Company will be required to pay the former shareholders of Jade a cash earnout payment in the event any product developed by Jade prior to its acquisition, or derivative of such product, receives FDA approval. However, due to the fact that the Company’s KIO-201 product candidate is now being developed as a drug rather than a device, the expected development time for KIO-201 has been extended. As a result of that extended timeline, the Company anticipates a reduction of the contingent consideration for KIO-201 as of December 31, 2021.

 

Additionally, in connection with the Company’s acquisition of Bayon Therapeutics, Inc. (“Bayon”) and Panoptes Pharma Ges.m.b.H (“Panoptes”) transactions in October 2021 and December 2020 respectively, the Company will be required to pay the former shareholders of Bayon and Panoptes cash earnout payments in the event developmental milestones are achieved. However, due to a reevaluation of the probability of success and discount rate for Bayon and Panoptes assets acquired, the Company anticipates a reduction of the contingent consideration as of December 31, 2021.

 

The Company is also evaluating the impact that the above adjustment may have on the Company’s goodwill and intangible asset impairment testing as of December 31, 2021. 

 

Based on the foregoing determination, the Company will correct the material misstatements in the Company’s previously issued consolidated financial statements as of and for the fiscal years ended December 31, 2021 and December 31, 2020 and condensed consolidated interim financial statements as of and for the fiscal periods ended March 31, 2021, June 30, 2021 and September 30, 2021 in a comprehensive amended Annual Report on Form 10-K for the fiscal year ended December 31, 2021 with expanded financial information and other disclosures in lieu of filing separate amended annual and quarterly reports for the affected periods during the fiscal years ended December 31, 2021 and December 31, 2020. 

  

The Company intends to file such amended reports as soon as practicable.

 

The Audit Committee discussed the matters described in this Item 4.02 with representatives of EisnerAmper.

 

 

 

 

Forward-Looking Statements

 

Certain statements included in this Form 8-K are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding the effects of the restatement of the Company’s past financial statements and the expected timing of filing of the Company’s amended periodic reports. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that include terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and the Company’s other filings with the SEC. Except as required by law, the Company assumes no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.

  

Item 9.01. Financial Statements and Exhibits.

 

  (d) Exhibits.

 

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

  KIORA PHARMACEUTICALS, INC.
   
     
  By: /s/ Brian M. Strem, Ph.D.
    Brian M. Strem, Ph.D.
    President and Chief Executive Officer
   
   
  Date: May 23, 2022

  

 

EX-101.SCH 2 kprx-20220520.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 kprx-20220520_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 kprx-20220520_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
May 20, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 20, 2022
Entity File Number 001-36672
Entity Registrant Name KIORA PHARMACEUTICALS, INC.
Entity Central Index Key 0001372514
Entity Tax Identification Number 98-0443284
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1371 East 2100 South
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Salt Lake City
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84105
City Area Code 781
Local Phone Number 788-9043
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol KPRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 tm2216631d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001372514 2022-05-20 2022-05-20 iso4217:USD shares iso4217:USD shares 0001372514 false 8-K 2022-05-20 KIORA PHARMACEUTICALS, INC. DE 001-36672 98-0443284 1371 East 2100 South Suite 200 Salt Lake City UT 84105 84105 781 788-9043 false false false false Common Stock, $0.01 par value KPRX NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://eyegatepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2216631d1_8k.htm kprx-20220520.xsd kprx-20220520_lab.xml kprx-20220520_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2216631d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2216631d1_8k.htm" ] }, "labelLink": { "local": [ "kprx-20220520_lab.xml" ] }, "presentationLink": { "local": [ "kprx-20220520_pre.xml" ] }, "schema": { "local": [ "kprx-20220520.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "KPRX", "nsuri": "http://eyegatepharma.com/20220520", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2216631d1_8k.htm", "contextRef": "From2022-05-20to2022-05-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://eyegatepharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2216631d1_8k.htm", "contextRef": "From2022-05-20to2022-05-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 13 0001104659-22-063871-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-063871-xbrl.zip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